BioSpace News Archive

The easy-to-clean, glove-operable touchpad can help everyone from first responders to medical staff to average citizens help fight the spread of COVID-19

Denovo Biopharma LLC, a pioneer in applying precision medicine to develop innovative therapies, today announced it is acquiring Tocagen’s retroviral replicating vector platform (RRV) in its entirety, including its investigational gene therapy and drug regimen for oncology: Toca 511 and Toca FC (now known as DB107), and several early-stag

Illumina, Inc. (NASDAQ: ILMN) is pleased to announce that the African Union Commission, on behalf of the Africa Center for Disease Control and Prevention (CDC), is receiving a $1.4 million donation of our sequencing systems and related consumables intended to expand SARS-CoV-2 sequencing capabilities and capacity in ten African countries, including the Democratic Republic of the Congo, Egypt, Ethiopia, Ghana, Kenya, Mali, Nig

- Now available in a third vial size (3-mL - 900-IU), HyperRAB, the only high-potency formulation of rabies immunoglobulin, gives healthcare professionals more convenient dosing options, reduces storage space and minimizes unnecessary waste - HyperRAB is presently the number one prescribed rabies immunoglobulin in the U.S., with over 1 billion international units administered to more than 1 million patients over 45 years - Grifols continues to expand its leadership in disease

VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce that the Company’s annual financial statements and management discussion and analysis for the year ended December 31, 2019 are now available to download on the Company’s website at www.vaxil-bio.com/ and on Sedar at www.sedar.com . The following is a summary

Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases, today announced the pricing of an underwritten public offering of 11,652,830 shares of its common stock at a price to the public of $4.75 per share. In addition, and in lieu of common stock, Aeglea is offering to certain investors pre-funded warra

Sales Rep Training, Forecasting, Competitive Intelligence, Patient Support Services, and KOL Relationship Management among the Functions within the Pharmaceutical Commercial Model Most in Need of Change During and Post-Pandemic

Todos Medical Ltd. (OTCQB: TOMDF) , a commercial in vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, as well as point-of-care and lab-based tests for novel coronavirus (COVID-19 or COVID), today announced positive data for its Colloidal Gold point-of-care (POC) 2 to 10 minute fingerprick blood antibody test

PITTSBURGH, April 28, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE), a preclinical-stage biotechnology company focused on developing next generation therapies to treat rare genetic diseases caused by mutant genes, announced today the pricing of an underwritten public offering of 5,250,000 shares of its common stock, at a price to the public of $6.00 per share. The gross proceeds to NeuBase from the offering, before deducting the underwriting discounts and commissions and o

[28-April-2020] LUND, Sweden , April 28, 2020 /PRNewswire/ -- Immunovia has today published first quarter interim report for January - March 2020 . It is available on Immunovia’s website . “During Q1 2020, Immunovia worked hard and continued to make great strides towards IMMray™ PanCan-d’s launch and the sales start of the first test for early diagnosis of pancreatic cancer, in spite of